» Authors » M Nijhuis

M Nijhuis

Explore the profile of M Nijhuis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 31
Citations 1222
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Buchholtz N, Nuhn M, de Jong T, Stienstra T, Reddy K, Ndungu T, et al.
Virol J . 2024 Jan; 21(1):36. PMID: 38297379
Introduction: HIV reservoir quantification is essential for evaluation of HIV curative strategies and may provide valuable insights about reservoir dynamics during antiretroviral therapy. The Intact Proviral DNA Assay (IPDA) provides...
2.
Umunnakwe C, Makatini Z, Mdunyelwa A, Mphanga M, Nijhuis M, Wensing A, et al.
S Afr Med J . 2022 Feb; 112(2):13499. PMID: 35139987
We describe a case of prolonged SARS-CoV-2 RNA shedding in an HIV-negative 21-year-old man recovering from abdominal and thoracic trauma. Nasopharyngeal (NP) swabs collected at 12 time points over a...
3.
van Lelyveld S, Symons J, van Ham P, Connell B, Nijhuis M, Wensing A, et al.
Int J Antimicrob Agents . 2015 Nov; 47(1):84-90. PMID: 26585497
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the...
4.
Bosman K, Nijhuis M, van Ham P, Wensing A, Vervisch K, Vandekerckhove L, et al.
Sci Rep . 2015 Sep; 5:13811. PMID: 26350506
HIV persists in latently infected cells of patients on antiretroviral therapy (ART). This persistent proviral DNA reservoir is an important predictor of viral rebound upon therapy failure or interruption and...
5.
Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, et al.
Clin Microbiol Infect . 2011 Sep; 18(6):606-12. PMID: 21906210
Guidelines state that the CCR5-inhibitor Maraviroc should be prescribed to patients infected with R5-tropic HIV-1 only. Therefore, viral tropism needs to be assessed phenotypically or genotypically. Preliminary clinical trial data...
6.
van Lelyveld S, Nijhuis M, Baatz F, Wilting I, van den Bergh W, Kurowski M, et al.
Clin Infect Dis . 2010 Jan; 50(3):387-90. PMID: 20047481
We report the selection of enfuvirtide-resistant human immunodeficiency virus type 1 in cerebrospinal fluid, resulting in subsequent loss of viral suppression in the plasma. This case report emphasizes the potential...
7.
Nijhuis M, van Maarseveen N, Boucher C
Handb Exp Pharmacol . 2008 Dec; (189):299-320. PMID: 19048205
Resistance development is a major obstacle to antiviral therapy, and all active antiviral agents have shown to select for resistance mutations. Aspects of antiviral resistance development are discussed for specific...
8.
van Maarseveen N, Huigen M, de Jong D, Smits A, Boucher C, Nijhuis M
J Virol Methods . 2005 Dec; 133(2):185-94. PMID: 16368153
The emergence of drug-resistant viruses is a major issue in the treatment of HIV-1 infections. Quite often these drug-resistant viruses have a reduced replication capacity. A novel assay was developed...
9.
van Elden L, van Loon A, van der Beek A, Hendriksen K, Hoepelman A, van Kraaij M, et al.
J Clin Microbiol . 2003 Sep; 41(9):4378-81. PMID: 12958272
Respiratory syncytial virus (RSV) accounts for the majority of respiratory virus infections, producing high mortality rates in immunocompromised patients with hematologic malignancies. The available methods for the rapid detection of...
10.
Verboon-Maciolek M, Nijhuis M, van Loon A, van Maarssenveen N, van Wieringen H, Pekelharing-Berghuis M, et al.
Clin Infect Dis . 2003 Jun; 37(1):1-6. PMID: 12830402
During summer and fall, enterovirus infections are responsible for a considerable proportion of hospitalizations of young infants. We prospectively studied the incidence of enterovirus infections via real-time polymerase chain reaction...